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yocardial Perfusion Imaging
nd Multidetector Computed
omographic Coronary Angiography
ppropriate for All Patients With
uspected Coronary Artery Disease?*
harmila Dorbala, MBBS, FACC,†
ory Hachamovitch, MD, MSC, FACC,‡
arcelo F. Di Carli, MD, FACC†
oston, Massachusetts; and Los Angeles, California
ver the last 5 years, we have witnessed an impressive
ntroduction of new imaging technology for the evaluation
f patients with known or suspected coronary artery disease
CAD). The introduction of multidetector computed tomo-
raphic (CT) scanners with submillimeter spatial resolution
nd subsecond gantry rotations has revolutionized the field
f cardiac imaging by making “direct” noninvasive imaging
f the coronary arteries possible. The application of this
echnology in the form of CT coronary angiography (CTA)
esults in an accurate test for excluding coronary athero-
clerosis with a very high negative predictive value
95%), especially when using 16- or 64-slice CT (1). The
See page 2508
se of CTA also provides excellent diagnostic sensitivity for
dentifying stenoses in the proximal and middle segments
1.5 mm in diameter) of the main coronary arteries.
nlike invasive coronary angiography, CTA not only as-
esses disease within the coronary lumen but also provides
irect qualitative and quantitative information about non-
bstructive atherosclerotic plaque burden and its composi-
ion. Thus, it is possible that CTA-based patient evaluation
ay provide more clinically relevant information upon
hich to base risk assessments compared with conventional
lumenography.”
Consequently, CTA is without a doubt a powerful
oninvasive modality for evaluating and excluding CAD—
ith respect to both obstructive stenoses and atherosclerosis—
nd it will likely play an important role in the diagnosis of
AD. Before the widespread clinical application of CTA to
aily practice, however, major questions must be answered.
or example, where in a testing algorithm will this test fit?
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Divisions of Nuclear Medicine/PET and Cardiovascular Imaging,
epartment of Radiology, Brigham and Women’s Hospital, Harvard Medical School,f
oston, Massachusetts; and the ‡Cardiovascular Medicine Division, Department of
edicine, University of Southern California, Los Angeles, California.oes it replace exercise treadmill testing, stress myocardial
erfusion imaging (MPI), both, or neither? Who are ap-
ropriate candidates for CTA? To this end, defining the
ole of CTA in a patient testing algorithm awaits the results
f investigations defining the relative roles and capabilities
f CTA compared with conventional noninvasive testing.
OMPARING CTA AND STRESS SPECT
n this issue of the Journal, Schuijf et al. (2) evaluate the
elationship between CTA and single-photon emission
omputed tomography (SPECT) MPI in a cohort of 114
atients with predominantly intermediate pretest likelihood
f CAD undergoing both tests within 30 days of each other.
he 2 noninvasive imaging approaches were also compared
ith respect to their accuracy in identifying coronary anat-
my as defined by invasive coronary angiography in a
ubgroup of 58 patients. The CTA was performed using 16-
nd 64-slice CT in 28 and 86 patients, respectively. The
PI was performed using either bicycle exercise, dobut-
mine, persantine, or adenosine stress combined with a
echnetium-99m imaging agent.
TA versus invasive coronary angiography. Overall, only
6% of patients (46% of coronary vessels) in this study
howed normal coronary arteries on CTA. Confirming
revious studies, the agreement between CTA and invasive
oronary angiography was excellent, with 52 of 58 patients
eing correctly diagnosed as either no CAD (9 of 9),
onobstructive CAD (stenosis50%, 16 of 16), or obstruc-
ive CAD (stenosis 50%, 27 of 33). Six patients (10%)
howed obstructive CAD on CTA but only mild disease on
nvasive coronary angiography.
TA versus MPI. There was greater discordance between
TA and MPI results. On the one hand, most patients with
ormal CTA also showed normal myocardial perfusion
n  37; 90%). However, only 45% (33 of 73) patients with
bnormal CTA showed corresponding perfusion abnormal-
ties on stress SPECT; that is, 20 of 40 patients (50%) with
bstructive CAD on CTA, and 13 of 33 patients (39%)
ith nonobstructive CAD had MPI abnormalities. These
ndings also confirm earlier studies (3–5).
The low frequency (59%) of perfusion defects in the
roup with obstructive CAD on invasive angiography may
e attributed to a balanced reduction in myocardial perfu-
ion. This approach often underestimates the extent of
nderlying anatomic CAD owing to the compromised
oronary vasodilator reserve in patients with CAD even in
erritories supplied by noncritical angiographic stenoses (6),
hereby reducing the heterogeneity of flow between “nor-
al” and “abnormal” zones. However, on a per-patient
asis, the test has an excellent sensitivity to detect obstruc-
ive CAD (7), and only rarely is severe CAD missed by
tress SPECT (7). The excellent prognostic value associated
ith a normal stress SPECT further supports the lowrequency of such a phenomenon (7). The relatively high
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Editorial Comment December 19, 2006:2515–7requency (18%; 2 of 11 patients) of normal stress SPECT
n patients with 3-vessel CAD in the present study likely
eflects the small numbers of patients and/or selective
eferral to angiography of patients with ongoing symptoms.
The authors conclude that CTA and MPI appear to
rovide complementary information, the former regarding
therosclerosis and the latter regarding ischemia. These
esults also extend previous findings of CTA’s discrimina-
ion for anatomic end points to an intermediate likelihood
ohort.
HY THE DISCORDANCE BETWEEN
TA AND STRESS PERFUSION IMAGING?
istorically, numerous investigators have shown that ana-
omic measures of CAD have well-described limitations
ith respect to delineating the physiologic implications of
picardial coronary stenoses (8). First, percentage diameter
tenosis is only a modest descriptor of coronary resistance
hat does not incorporate other lesion characteristics (e.g.,
ength, shape, eccentricity) or stenoses in series that may
reatly affect the impedance to blood flow. Second, vaso-
otor tone and coronary collateral flow, both of which are
nown to affect myocardial perfusion, are not assessed by
imple measures of stenosis severity. In contrast, MPI
rovides a simple and accurate integrated measure of the
ffect of all these parameters on coronary resistance and
issue perfusion. It follows, as shown by numerous studies
ver the last 3 decades, that physiologic approaches to
efining CAD risk—whether stress electrocardiography,
tress perfusion, or direct invasive measures of coronary flow
eserve—are superior to anatomic measures with respect to
linical and cost-effectiveness end points (7,9–11).
In addition to the intrinsic limitations associated with
natomic measures, there are additional limitations to the
TA technique that introduce further error into the esti-
ation of coronary anatomy by this technique. Recent
vidence obtained with 64-slice CT indicates that quanti-
ative estimates of stenosis severity (as a surrogate for
hysiologic significance) by CT correlate only modestly
ith quantitative coronary angiography, the former explain-
ng only 29% of variability in the later (12). Image degra-
ation by motion, calcium, and metal implants may all
ontribute to under- and overestimation of luminal narrow-
ng by CTA. These factors may explain the significant
iscrepancies observed between the frequency of anatomic
AD by CTA and functionally significant stenoses by stress
erfusion imaging, as evidenced by increasing evidence that
natomic-based predictions of physiologic significance by
TA differ substantially from direct measures of inducible
yocardial ischemia (3–5). Finally, the referral biases inher-
nt in many studies, including the present report, comparing
hese modalities (especially with respect to why a patient
ould have been sent to CTA versus MPI as an initial test,
ecruitment rates from CTA vs. MPI, and so on) further
bfuscate these results. Thus, the enthusiasm for CTA as a
m
aotential noninvasive tool for guiding patient management
ecisions is tempered for many clinicians by a growing
wareness that CTA may be limited in defining physiologic
ignificance of coronary stenoses and, therefore, defining
hich patients may potentially benefit from a revasculariza-
ion strategy.
ELECTING IMAGING TESTS FOR CAD
n patients with a low to intermediate (15% to 50%) pre-test
ikelihood of CAD the performance characteristics of con-
entional tests such as exercise treadmill testing or nuclear
erfusion imaging limit definitive exclusion of CAD. In
ontrast, the expected frequency of normal CTA is high,
nd its use as an initial test may decrease downstream
esource use and aid patient management in symptomatic
ubjects. In asymptomatic subjects, the dye load and radia-
ion burden may limit the use of CTA for diagnostic
urposes, but a calcium score may be helpful to guide
ggressiveness of medical management.
However, this approach may not be applicable to patients
ith an intermediate to high (50% to 85%) pre-test likeli-
ood of CAD. Whether CTA will be a cost-effective first
tep depends on its relative cost, the prevalence of abnormal
TA in the cohort to be examined, and the number of
atients that can be identified as not needing further
valuation. If the prevalence of abnormal CTA is sufficiently
igh, or insufficient numbers of patients are spared further
esting, MPI would be a superior first step. The present
tudy and an earlier study (3) suggest that the frequency of
bstructive CAD on a CTA study is 33% (range 31% to
5%) in patients with low to intermediate or intermediate
ikelihood of CAD. This frequency in a higher-likelihood
ohort has not been described. In this cohort, MPI in
onjunction with or after CTA would also be justified.
pproximately 50% of patients (3) and one-third of the
oronary vessels with obstructive disease on CTA (2–5) may
igure 1. Value of multidetector computed tomographic coronary angiog-
aphy (CTA) for predicting ischemia on myocardial perfusion imaging
per-vessel basis). NPV  negative predictive value; PET  positron
mission tomography; SPECT  single-photon emission computed to-
ography; PPV  positive predictive value. Data adapted from Schuijf et
l. (2), Di Carli et al. (3), Hacker et al. (4), and Rispler et al. (5).
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December 19, 2006:2515–7 Editorial Commenthow no evidence of ischemia (Fig 1). Therefore, MPI
ould be necessary to identify appropriate candidates for
atheterization and revascularization, because this approach
ould not yield a benefit in patients without objective
vidence of ischemia or with only small amounts of ischemic
yocardium (9,11). Also, in patients with stable angina, a
trategy of invasive therapy as guided by SPECT MPI was
hown to be cost-effective with no increase in adverse
utcomes, compared with a direct invasive approach at all
evels of pre-test clinical risk. Indeed, the increased costs in
he direct invasive arm was related not only to the upfront
osts of a coronary angiogram but also to follow-up costs
elated to revascularization and other downstream costs
10). Because CTA has limited ability to define myocar-
ium jeopardized by ischemia, its potential for predicting
enefit from revascularization is limited. Therefore, evalu-
tion of ischemic burden by MPI as an initial test, with
TA reserved for discordant test results, may be the optimal
trategy for patients with intermediate to high pre-test
ikelihood of CAD.
In patients with a high pre-test likelihood of CAD
85%), a negative MPI study does not exclude the
iagnosis of atherosclerosis, whereas CTA is unlikely to
iss severe or extensive CAD. Except in patients with
igh-risk scan features, combined testing with SPECT and
TA may be an effective strategy to both diagnose extent of
AD and guide management to the appropriate vessel.
atients with high-risk features on MPI are best managed
y an invasive coronary angiogram with intent of revascu-
arization. Of course, the substantial radiation burden from
ombined evaluation with multidetector CT (7 to 12
Sv, chest dose) and MPI (15 mSv, whole-body dose)
eeds to be balanced against the potential risks of invasive
oronary angiography on a patient-by-patient basis.
The study by Schuijf et al. (2) demonstrates interesting,
lthough expected, differences between anatomic and phys-
ologic measures of atherosclerosis in diagnosis of CAD.
hese differences should be interpreted in the context of the
atient cohort studied and the potential selection bias in
ecruiting patients with 1 abnormal test or high clinical
uspicion for underlying obstructive CAD. Further, these
esults lead to more questions. Do the combined tests
rovide incremental clinical value over conventional tests?
re they cost-effective? Are both tests necessary (CTA and
PECT or positron emission tomography [PET], or hybrid
ET/CT or SPECT/CT), or in what sequence (CTA first
r SPECT first), and in which patient cohort (low, inter-
ediate, or high pre-test likelihood of CAD)? The Study of
yocardial Perfusion and Coronary Anatomy Imagingoles in CAD (SPARC) is a large prospective study registryecruiting 4,000 patients with known CAD or intermediate
o high likelihood of CAD at over 40 medical centers in the
.S. This study will evaluate the impact of SPECT, PET,
TA, and PET/CT on outcomes, post-test resource use,
nd cost. We hope that the results will provide us with
nswers to many of these questions.
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